Company Overview: Isoray

Industry News

28 Sep

IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase

Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash., Sept. 28, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced...

Read more

26 Sep

IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled “Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies”

Study Demonstrates Ability to Control Local Disease Over Reasonably Long Period of Time, A Major Step in Preserving Quality of Life RICHLAND, Wash., Sept. 26, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain,...

Read more

25 Sep

IsoRay Announces “Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial” Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference

9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash., Sept. 25, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today...

Read more

31 Aug

IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

Presenting on Monday September 11 at 12:05PM ET RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced it will be...

Read more

6 Jul

IsoRay Receives FDA Response to 510(k) Application for GammaTile™

RICHLAND, Wash., July 6, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it has received a response from the FDA regarding the Company’s...

Read more

20 Jun

IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, “Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial”

Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis RICHLAND, Wash., June 20, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today...

Read more

10 May

IsoRay Announces Third Quarter Fiscal 2017 Financial Results

RICHLAND, Wash., May 10, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced financial results for the third quarter of fiscal 2017, ended March...

Read more

3 May

IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

RICHLAND, Wash., May 3, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the acceptance for publication of a study entitled “Long-term...

Read more

18 Apr

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

NEW YORK, NY / ACCESSWIRE / April 18, 2017 / IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that it will be presenting at...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address